Chemotheraphy, Neurotoxicity, and Cognitive Decline: Developing a Mouse Model and Potential Interventions
Annual rept. 1 Sep 2010-31 Aug 2011
MAINE UNIV AT ORONO
Pagination or Media Count:
Adjuvant chemotherapy often causes cognitive decline in breast cancer survivors. Although the cognitive deficits are often temporary, it appears that for at least a subset of survivors, the deficits last for years and can have a deleterious impact on survivor quality of life. Recent evidence shows that chemotherapy agents can have long-lasting neurotoxic effects increase in cell death and decrease in cell divisionproliferation in the SVG, the DG, and the CC, as well as delayed myelin degeneration. Which chemotherapy agents or combinations of agents cause CNS damage remains unclear. Our study was designed to determine 1 if doxorubicin or cyclophosphamide cause a decrease in neurogenesis andor myelin damage and 2 if neurogenesis andor myelin damage caused by 5-Fluorouracil can be prevented by pre and co-treatment with antidepressants or antioxidants. The results from our auditory brainstem response experiments suggest that 5-Fluorouracil causes lasting myelin damage and that doxorubicin and cyclophosphamide do not. In addition, our results suggest that co-treatment with antioxidants does not prevent 5- Fluorouracil related myelin damage. Our immunocytochemistry experiments are ongoing and will help us determine if doxorubicin or cyclophosphamide cause a decline in neurogensis, as does 5-Fluorouracil, and if antidepressants or antioxidants can prevent such damage.
- Anatomy and Physiology
- Medicine and Medical Research